Dr. Ling Su is currently a Strategic Advisor in Sidley Austin’s China life sciences practice. Dr. Su has more than 20 years of experience working in regulatory agencies and the industry, in both US and Asia regions, covering a broad spectrum of drug development processes and functions and a variety of therapeutic areas. Most recently, Dr. Su was Senior Vice President and Head of Development Greater China Region at Novartis Pharma. Prior to that, he had worked as Epidemiologist, China Medical Director, Senior Director for Global Strategic Regulatory Development at Merck Sharp & Dohme; Medical and Pharma Development Director at Roche in Shanghai; and VP for Clinical Research and Development Asia Pacific Region at Wyeth. Prior to joining the industry, Dr. Su worked in the Bureau of Drugs of the Ministry of Health in China and in CDER, US FDA. Dr. Su is the President of the Drug Information Association (DIA), the first person from Asia to serve in this role. He is a member of the Pharmacoepidemiology Committee of the Chinese Pharmaceutical Association and an editorial board member of the Chinese Journal of Pharmacoepidemiology. He teaches a graduate student course in pharmacoepidemiology in School of Pharmacy, Fudan University, as an adjunct faculty. He also serves as the Advisory Committee Chair of the Chinese Course on the Drug Development and Regulatory Sciences (CCDRS) at Peking University Clinical Research Institute; and a Symposium Scholar on Drug Regulation and Evaluation in Shenyang Pharmaceutical University. Dr. Su graduated from Shanghai Medical University. He received his MS degree in Clinical Pharmacy and Drug Development and PhD in Epidemiology from University of North Carolina at Chapel Hill. His professional interests include regulatory affairs, product development strategy and management, clinical research, drug safety, pharmacovigilance and pharmacoepidemiology.